Stenotrophomonas maltophilia Bacteremia Associated With Severe COVID-19: Successful Treatment With Appropriate Antimicrobial Therapy

Masaatsu Kuwahara 1, Mitsuki Noma 1, Takuya Sunakawa 1, Kunihiro Shirai 1, Keisuke Kohama 1, Atsushi Miyawaki 1, Jun-ichi Hirata 1
1. Emergency and Critical Care Medicine, Hyogo College of Medicine, Nishinomiya, JPN

Abstract

Stenotrophomonas maltophilia, an opportunistic pathogen, can cause bacteremia in immunocompromised and debilitated patients. A 50-year-old man with severe coronavirus disease 2019 (COVID-19) was admitted to our hospital’s intensive care unit where he underwent extracorporeal membrane oxygenation and ventilatory support. On day 25, he developed S. maltophilia bacteremia originating from an indwelling central venous catheter. After confirming susceptibility, trimethoprim-sulfamethoxazole (80 mg/400 mg) was administered thrice daily. Following improvement, he was weaned from ventilation, recovered sufficiently, and was discharged on day 55. To the best of our knowledge, this is the first report of a patient recovering after antimicrobial treatment for S. maltophilia bacteremia associated with severe COVID-19.

Introduction

Stenotrophomonas (Xanthomonas) maltophilia, a ubiquitous, aerobic, nonfermentative, multidrug-resistant, Gram-negative, rod-shaped bacterium, is closely related to the genus Pseudomonas and can be an opportunistic pathogen, especially in hospitalized patients [1].

Pneumonia and bacteremia are the most common manifestations of S. maltophilia infection; most cases of S. maltophilia bacteremia are associated with an indwelling catheter [2]. Studies have demonstrated that 73% of 207 patients receiving oncologic treatment who had indwelling central venous catheters and S. maltophilia bloodstream infections had catheter-related infections, 22% had secondary infections (primarily pulmonary in origin), and 5% had primary infections unrelated to the catheter [3]. Because S. maltophilia is a multidrug-resistant organism, there are limited antibiotic options.

Stenotrophomonas maltophilia infections in severely immunocompromised and debilitated individuals are associated with high morbidity and mortality, with overall mortality rates ranging from 21% to 69% [4,5]. Intensive care unit admission and delay in effective treatment are independent risk factors for mortality [6].

The incidence of opportunistic infections like S. maltophilia may have increased during the coronavirus disease 2019 (COVID-19) pandemic because of the increased number of prolonged intensive care unit stays for extracorporeal membrane oxygenation (ECMO) and ventilation. Herein, we report the case of a patient with severe COVID-19 and S. maltophilia bacteremia who was successfully treated at our hospital and discharged.

Case Presentation

The patient was a 50-year-old man with a body mass index of 28 kg/m2 and no relevant medical history. He was a past smoker (20 cigarettes/day for 15 years) with no drinking or COVID-19 vaccination history. After being diagnosed with COVID-19 pneumonia by polymerase chain reaction, he was referred to our hospital and admitted to the intensive care unit because it was difficult to maintain oxygenation with normal oxygen therapy and ventilator management became necessary. Stenotrophomonas maltophilia was detected in blood cultures (two bottles/two sets) on day 25. Below, we describe his course of treatment before and after day 25 of hospitalization.

General condition

On the second day after admission to our hospital, the patient was found to have poor oxygenation and was subsequently intubated and placed on ventilation. On the seventh day of hospitalization, ECMO was...
initiated due to difficulty maintaining oxygenation despite ventilatory support. The patient’s oxygenation improved, enabling weaning from ECMO on day 25 of hospitalization, at which stage he still required mechanical ventilation.

**Drugs**

Tocilizumab (8 mg/kg/day) was administered on the first and second days of hospitalization for severe COVID-19. Steroids were administered as follows: dexamethasone (6 mg/day) for the first six days, methylprednisolone (250 mg) for three days from days seven to nine, methylprednisolone (80 mg) for nine days from days 10 to 18, methylprednisolone (40 mg) for five days from day 19 to 23, and, finally, prednisolone (20 mg/day), which was still being administered on day 25.

Antimicrobial therapy comprised ceftriaxone (2 g) once daily for four days from day four to seven as empirical therapy for ventilator-associated pneumonia, which was also treated empirically with ceftazidime (1 g) twice daily for two days on days 13 and 14. After the detection of extended-spectrum β-lactamase–producing *Klebsiella pneumoniae* in the patient’s sputum, meropenem (1 g) was administered thrice daily for eight days from days 14 to 21. The patient was de-escalated to cefmetazole sodium (1 g) thrice daily for four days from days 22 to 25.

*Stenotrophomonas maltophilia* was detected in the sputum on the fourth day of hospitalization, after that, it continued to be detected. However, because there was no associated worsening of respiratory symptoms, the patient was considered to be a carrier. Thus, no treatment was initiated for *S. maltophilia* infection at this time.

**Course from day 25**

On day 25, the patient had a fever of 38.4 °C, and *S. maltophilia* was detected in blood cultures taken to identify the source of infection. This organism was also detected in the central venous catheter tip submitted for analysis on the same day. Thus, bacteremia due to catheter infection was diagnosed. Because the organism was strongly sensitive to trimethoprim-sulfamethoxazole (TMP-SMX) (minimum inhibitory concentration ≤ 1), TMP-SMX was started at 80 mg/400 mg thrice daily (the standard treatment for *S. maltophilia* infection). The patient’s general condition improved, and he was successfully weaned from the ventilator and extubated on day 28. Trimethoprim-sulfamethoxazole was administered intravenously for 14 days from days 25 to 38. Subsequently, the patient recovered sufficiently for discharge on day 53 of hospitalization.

**Discussion**

We present a rare case of bacteremia caused by *S. maltophilia* during severe COVID-19 infection. Only one case of bacteremia caused by *S. maltophilia* has been reported in a patient with severe COVID-19, and that patient ultimately died [7]. In the present case, *S. maltophilia* bacteremia during severe COVID-19 was successfully treated with antimicrobial therapy.

Risk factors associated with *S. maltophilia* infection include intensive care unit admission, human immunodeficiency virus (HIV) infection, malignancy, cystic fibrosis, neutropenia, mechanical ventilation, indwelling central venous catheter, recent surgery, trauma, and history of broad-spectrum antibiotic treatment [9]. In the present case, the following risk factors were present: intensive care unit admission, indwelling central venous catheter, and history of broad-spectrum antibiotic treatment. Most cases of *S. maltophilia* bacteremia are associated with an indwelling catheter, which was also the case with our patient.

Treatment of severe COVID-19 inevitably requires intensive care unit admission. Additionally, broad-spectrum antibiotic therapy for secondary infection is frequently needed. Furthermore, these patients require many other drugs, including sedatives, analgesics, and hypertensive agents, making the insertion of a central venous catheter essential. In addition, long-term ventilation, tracheostomy, and ECMO are all more frequently required by patients with severe COVID-19 than by those with other diseases that require mechanical ventilation.

The administration of dexamethasone has been shown to reduce mortality in patients with COVID-19 [9] and, thus, the current standard of care. However, this may result in steroid-induced immunosuppression. It is, therefore, necessary to consider *S. maltophilia* as a possible cause of bacteremia in patients with severe COVID-19.

*Stenotrophomonas maltophilia* infections should be treated promptly with antibiotics because any delay of appropriate treatment can lead to significant mortality. Given that *S. maltophilia* is a multidrug-resistant organism, antibiotic options are limited. Trimethoprim-sulfamethoxazole is the antibiotic combination of choice because of its reliable in vivo activity against *S. maltophilia* [10]. In the present case, we confirmed the organism’s susceptibility to TMP-SMX; prompt administration of this antibiotic combination led to a good outcome. Notably, our patient was about 10 years younger than the one reported by Pek et al. [7], and improvements in the treatment of COVID-19 since they treated their patient may have contributed to our
patient's good outcome.

Nevertheless, the present case provides some points for reflection. In particular, S. maltophilia was detected by sputum culture on the fourth day of hospitalization. At this point, we judged that he was only a carrier, rather than having an infection and accordingly did not administer any treatment. However, it may have been preferable to initiate TMP-SMX treatment when bacteremia was first suspected.

Conclusions

It is necessary to consider S. maltophilia as a possible cause of bacteremia in patients with severe COVID-19. It may be better to start treatment with TMP-SMX when bacteremia is suspected, especially for S. maltophilia carriers. In conclusion, to the best of our knowledge, this is the first case report of a patient with severe COVID-19 and S. maltophilia bacteremia who was successfully treated and discharged home.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Calza L, Manfredi R, Chiodo F: Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection. 2003, 31:155-161. 10.1007/s15010-003-3113-6
2. Lai CH, Chi CY, Chen HP, et al.: Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004, 37:1559-167. 10.1002/jmii.21846
3. Boktour M, Hanna H, Ansari S, et al.: Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006, 106:1967-1973. 10.1002/ijc.21846
4. Paez JR, Costa SF: Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008, 70:101-108. 10.1016/j.jhin.2008.05.020
5. Hashimoto T, Komiyama K, Fujita N, et al.: Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteremia. Infect Dis (Lond). 2020, 52:440-442. 10.1080/23744235.2020.1734653
6. Kwa ALH, Low JG, Lim TP, Leow PC, Kurup A, Tam VH: Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008, 37:826-830.
7. Pek Z, Cabanilla MG, Ahmed S: Treatment refractory Stenotrophomonas maltophilia bacteraemia and pneumonia in a COVID-19-positive patient. BMJ Case Rep. 2021, 14:e242670. 10.1136/bcr-2021-242670
8. Paez JR, Tergan FM, Barone AA, Levin AS, Costa SF: Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2008, 27:901-906. 10.1007/s10096-008-0518-2
9. Horby P, Lim WS, Emberson JR, et al.: Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:e93-704. 10.1056/NEJMoa2104356
10. Sader HS, Farrell DJ, Flamm RK, Jones RN: Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014, 43:328-334. 10.1016/j.ijantimicag.2014.01.007